Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 679

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 679
---
 $20,000,000. TuHURA has not currently executed any subscription agreement in connection with the contemplated Concurrent Investment. The Concurrent Investment is presented in the unaudited pro forma condensed combined financial statement as contemplated since it is a condition of closing of the Mergers. The Concurrent Investment is currently estimated for purposes of these pro formas to be the issuance of 4,952,579 shares of TuHURA Common Stock at a purchase price of approximately $4.0383 per share (estimated based on the 10-day VWAP of the TuHURA share price as of April 30, 2025) resulting in net proceeds of $18,400,000 after taking into account $1,600,000 of equity issuance costs recognized as a reduction to Additional paid-in capital (the Concurrent Investment is reflected within Pro Forma Adjustment C in Note 4 of the notes to the unaudited pro forma condensed combined financial information).

The Merger Agreement has been unanimously approved by the boards of directors of both companies and is subject to Kineta stockholder approval. The completion of the Proposed Transaction is also subject to the satisfaction or waiver of certain other conditions, such as the approval by TuHURA’s stockholders of an increase in the number of authorized shares of TuHURA common stock, Kineta’s working capital deficit not exceeding $6,000,000 at the time of closing, the effectiveness of a registration statement on Form S-4 registering the shares of TuHURA common stock issuable to the Kineta stockholders in the Mergers, and other customary closing conditions. The Proposed Transaction is currently expected to close in the second quarter of 2025. Pursuant to the Merger Agreement, if the Proposed Transaction has not been or is not expected to be completed by June 30, 2025, TuHURA may provide written notice on or prior to that date to extend the End Date to no later than July 31, 2025, provided that as a condition to making such extension, TuHURA shall advance to the Company an amount equal to $250,000 to fund additional Kineta expenses, of which the amount shall not increase the Loaned Amount for the purposes of calculating the Merger Consideration.

<div align='center'>442</div>

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Note 2. Basis of Presentation Kintara Merger (Reverse Recapitalization) The Kintara Merger was accounted